Dec. Volume 3, No.3

Infectious Disease

 

Cell-based membrane fusion assays with viral fusion proteins for identification of entry inhibitors
Mizuki YAMAMOTO, Jin GOHDA
Translat Regulat Sci.  2020 Dec, 3(3):  72-76
PDF      Full view HTML

 

Kenzo BAMBA, Midori OZAWA, Miho TAMAI, Emiko SHIMBO, Hiromasa SHINDO, Takuo OTA, Sungho AHN, Arihiro KOHARA, Yoh-ichi TAGAWA
Translat Regulat Sci.  2020 Dec, 3(3): 77-82
PDF       Full view HTML

 

Toward control of severe acute respiratory syndrome coronavirus 2 disease (COVID-19)
Masaki IMAI, Yoshihiro KAWAOKA
Translat Regulat Sci.  2020 Dec, 3(3): 83-84
PDF        Full view HTML

 

Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials
Marwa AKAO, Joohyeon WOO, Shingo IWAMI, Shoya IWANAMI
Translat Regulat Sci.  2020 Dec, 3(3): 85-88
PDF        Full view HTML

 

Identification of G-quadruplex sequences in severe acute respiratory syndrome coronavirus 2
Shogo SASAKI, Junya KITAMURA, Hiroyuki ENDO, Akira SHIRAISHI, Kazunori IKEBUKURO, Tetsuya MIZUTANI, Masayuki TERA
Translat Regulat Sci.  2020 Dec, 3(3): 89-92
PDF         Full view HTML

 

Enteral ventilation technology to combat severe respiratory failure
Yosuke YONEYAMA, Ryo OKABE, Takanori TAKEBE
Translat Regulat Sci.  2020 Dec, 3(3): 93-97
PDF          Full view HTML

 

Ameliorative effect of anti-complement factor antibody on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected macaque
Yasunori NIO
Translat Regulat Sci.  2020 Dec, 3(3): 98-101
PDF           Full view HTML

 

Simple and rapid RNA detection using cationic copolymer-chaperoned MNAzyme (ACEzyme)
Naoki YOSHIDA, Orakan HANPANICH, Raito HAYASHI, Naohiko SHIMADA, Atsushi MARUYAMA
Translat Regulat Sci.  2020 Dec, 3(3): 102-105
PDF            Full view HTML

 

Predictive serum markers for severe COVID-19 illness
Masaya SUGIYAMA
Translat Regulat Sci.  2020 Dec, 3(3): 106-108
PDF            Full view HTML

 

Yasushi ITOH
Translat Regulat Sci.  2020 Dec, 3(3): 109-111
PDF            Full view HTML

 

Open collaborative framework providing severe acute respiratory syndrome coronavirus 2 infection cell culture assays for accelerating drug development
Koichi WATASHI
Translat Regulat Sci.  2020 Dec, 3(3): 112-114
PDF             Full view HTML

 

Study protocol for a randomized, open-label, non-controlled Phase I/II Study to assess safety and immunogenicity of twice or three times dosing of intramuscular COVID-19 DNA vaccine in healthy adults
Hironori NAKAGAMI, Hiroki HAYASHI, Tetsuya ISHIHAMA, Yuichi DAIKYOJI, Chieka SASAKURA, Tadashi MIKAMI, Takao KOMATSUNO, Yoshimi SAITO, Kazuo SUZUKI, Akihiko MURAKAMI, Naoya SATO, Ei YAMADA, Hiromi RAKUGI, Ryuichi MORISHITA
Translat Regulat Sci.  2020 Dec, 3(3): 115-117
PDF              Full view HTML

 

Development of an mRNA vaccine against COVID-19
Masayuki YABUTA, Fumihiko TAKESHITA, Shizuko UENO, Natsuki TANAKA, Takahiro YANO, Keiji OE, Chie NIKAIDO, Ken J. ISHII, Masaki IMAI, Yoshihiro KAWAOKA, Toru TANZAWA
Translat Regulat Sci.  2020 Dec, 3(3): 118-119
PDF               Full view HTML

 

Development of an inactivated COVID-19 vaccine
Kengo SONODA
Translat Regulat Sci.  2020 Dec, 3(3): 120-121
PDF               Full view HTML

 

Development of intranasal Sendai virus vector-based vaccine against COVID-19
Ryutaro SHIMAZAKI, Kohji KUSANO
Translat Regulat Sci.  2020 Dec, 3(3): 122-124
PDF               Full view HTML